CancerDrs

Lymphoma clinical trials in North Carolina

45 actively recruiting lymphoma trials at 27 sites across North Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
  • Durham VA Medical Center — Durham, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in North Carolina:
  • Mission Hospital — Asheville, North Carolina
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Novant Health Presbyterian Medical Center — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Novant Health Presbyterian Medical Center — Charlotte, North Carolina
  • Wake Forest University at Clemmons — Clemmons, North Carolina
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …

Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in North Carolina:
  • Research Site — Charlotte, North Carolina
  • Research Site — Wilmington, North Carolina
  • Research Site — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…

Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in North Carolina:
  • University of North Carolina At Chapel Hill — Chapel Hill, North Carolina
  • Atrium Health Levine Cancer Institute (Lci) — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in North Carolina:
  • Carolina Oncology Specialists, PA ( Site 0054) — Charlotte, North Carolina
  • Southeastern Medical Oncology Center ( Site 0049) — Goldsboro, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…

Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in North Carolina:
  • Atrium Health Levine Cancer Institute (Lci) — Charlotte, North Carolina
  • Duke University — Durham, North Carolina
  • Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in North Carolina:
  • University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center (Adults and Pediatrics) — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Children's Hospital (Adults and Pediatrics) — Charlotte, North Carolina
  • Duke Cancer Institute (Adults and Pediatrics) — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…

Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in North Carolina:
  • North Carolina Cancer Hospital — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in North Carolina:
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
  • Levine Cancer Institute-Gaston — Gastonia, North Carolina
  • Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
  • Southeastern Medical Oncology Center-Jacksonville — Jacksonville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • East Carolina University — Greenville, North Carolina
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearran…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06649812
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in North Carolina:
  • University of North Carolina Medical Center ( Site 0136) — Chapel Hill, North Carolina
  • Novant Health Presbyterian Medical Center ( Site 0177) — Charlotte, North Carolina
  • Novant Health Forsyth Medical Center ( Site 0206) — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…

Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in North Carolina:
  • Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…

Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in North Carolina:
  • Duke University Medical Center - Division of Hematologic Malignancies — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…

Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in North Carolina:
  • Duke University Medical Center, Duke Cancer Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have receive…

Sponsor: AstraZeneca
NCT ID: NCT06526793
Sites in North Carolina:
  • Research Site — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…

Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in North Carolina:
  • East Carolina University — Greenville, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia …

Sponsor: Tanja Andrea Gruber
NCT ID: NCT05848687
Sites in North Carolina:
  • Novant Health - Hemby Children's Hospital — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

Sponsor: AstraZeneca
NCT ID: NCT06564038
Sites in North Carolina:
  • Research Site — Charlotte, North Carolina
  • Research Site — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

MB-105 in Patients With CD5 Positive T-cell Lymphoma

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.

Sponsor: March Biosciences Inc
NCT ID: NCT06534060
Sites in North Carolina:
  • University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT06533579
Sites in North Carolina:
  • University of North Carolina at Chapel Hill/ University of North Carolina Medical Center — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

A Study of Revumenib and Mezigdomide in People With Leukemia

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07356154
Sites in North Carolina:
  • University of North Carolina (Data Collection Only) — Chapel Hill, North Carolina
View on ClinicalTrials.gov →

Showing 25 of 45 trials with sites in North Carolina. See all lymphoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12